Drug Trial Radar · NCT06492304
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Aug 13, 2024
Primary completion
Mar 11, 2026
Study completion Mar 11, 2026
Sponsor
- Lead sponsor
- CRISPR TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies
Conditions
- T Cell Lymphoma
- B Cell Lymphoma
- Acute Myeloid Leukemia
Interventions
CTX131Biological
CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 Part A (dose escalation) and Part B (dose optimization in selected disease types):Time frame: From CTX131 infusion up to 28 days post-infusion
- Objective Response rate (ORR)Time frame: From CTX131 infusion up to 60 months post-infusion
- Composite Complete Remission (CRc)Time frame: From CTX131 infusion up to 60 months post-infusion
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Research Site 6
Phoenix, Arizona
Research Site 5
Stanford, California
Research Site 3
Boston, Massachusetts
Research Site 4
New York, New York
Research Site 2
The Bronx, New York
Research Site 1
Houston, Texas
Research Site 7
East Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.